- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01702662
Photopill Treatment in Healthy Volunteers (Photopill)
The Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Healthy Volunteers, a Phase 1 Trial
Photo-bio-stimulation by Low Level Light therapy(LLLT) has demonstrated its clinical use in chemotherapy/radiotherapy oral mucositis.
Unpublished study (Melzer, Ben-Yehuda et al. UEGW 2012) with the Photopill (LLLT) capsule treatment in mice showed a significant beneficial effect on the endoscopic severity of DSS-induced colitis in mice.
Therefore a phase 1 trial is designed to assess the safety and feasibility of the Photopill treatment in healthy volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1105 AZ
- Academic Medical Center Amsterdam, department of Gastroenterology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who are generally healthy.
- Signed informed consent.
Exclusion Criteria:
- Subjects with any known GI related symptoms complaints or GI diseases.
- Subjects with cancer or other life threatening diseases or conditions.
- Subjects with cardiovascular or pulmonary diseases.
- Pregnant women.
- Subjects who underwent any colon surgery.
- Morbid Obesity (BMI > 40).
- Drug abuse or alcoholism.
- Bed-ridden patient.
- Any rectal therapy.
- Participation in current clinical study or clinical study within 30 days prior to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Photopill treatment
Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
|
2 courses of 5 Photopill treatments within 14 days.
In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Adverse Events (Mucosal Aspect at 2nd sigmoidoscopy after 7-14 days) as a Measure of Safety and Tolerability
Time Frame: During Study period: day 0-14
|
During Study period: day 0-14
|
Collaborators and Investigators
Investigators
- Principal Investigator: Geert D'Haens, Prof.dr, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC2012_150, ABR: 40642
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.